Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag in inoperable or persistent/recurrent CTEPH
MOH_2018-12-30_004810Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Selexipag with Placebo (2 arms). Started Dec 2018; status: completed.
02
Drugs
selexipag
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on MOH_2018-12-30_004810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-30_004810.